The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patterns of concurrent chemotherapy selection in US patients undergoing trimodality therapy for muscle-invasive bladder cancer.
 
Eryn Callihan
No Relationships to Disclose
 
Elizabeth Molina Kuna
No Relationships to Disclose
 
Tyler P. Robin
No Relationships to Disclose
 
Corbin J. Eule
No Relationships to Disclose
 
Simon P. Kim
No Relationships to Disclose
 
Thomas W. Flaig
Leadership - Aurora Oncology; University of Colorado/UC Health
Stock and Other Ownership Interests - Aurora Oncology
Consulting or Advisory Role - Janssen Oncology; Seagen
Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Criterium; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Seagen; Sotio; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or in active clinical development right now (e.g. neither are in clinical trials).